Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreBringing together unparalleled healthcare data, advanced analytics, innovative technologies, and healthcare expertise to create intelligent connections that speed the development and commercialization of innovative medicines to improve patient lives.
Learn MoreAccelerate digital innovation to enable smarter decisions that reduce cost, modernize patient and consumer engagement, and improve health outcomes.
Learn MoreYour world is unique – and quite different from pharma. In the U.S., decision-making has shifted from individual physicians to integrated networks--GPOs, IDNs and payers. These groups have heightened the focus on proving your solution’s value, demanding outcomes analyses and putting pressure on pricing.
Learn MoreFor government agencies and organizations at every level—from federal or national to regional and local—Big Data can have a huge impact on public health.
Learn MoreA curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREGet the latest insights on our life sciences, healthcare, and medical technology solutions in the United States. Follow our blog today!
LEARN MOREThe U.S. Food and Drug Administration (FDA) guidance on real-world evidence (RWE) underscores the need for early engagement with the Agency to discuss real-world data (RWD) sources and non-interventional study designs prior to regulatory submission.
Join us for this webinar when we will explore how a robust and multidisciplinary feasibility methodology can de-risk regulatory and scientific strategy for external comparator studies. We will discuss key considerations for conducting feasibility assessment for external comparators utilizing RWD for regulatory submission, and strengthen understanding of these concepts through illustrative case studies.
Leanne Li, MPH, MBA
Sr. Principal, Regulatory Science & Study Innovation, IQVIA
Mayank Raizada, MS
Principal, Regulatory Science & Study Innovation, IQVIA
Julien Heidt, MS
Sr. Consultant, Regulatory Science & Study Innovation, IQVIA
Dony Patel, PhD
Director, Global Database Studies, IQVIA
Meet your clinical, economic, and regulatory needs throughout a product's lifecycle